Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
C1 esterase inhibitors
4 evidence topics · 4 sources
International/Canadian guideline: first-line long-term prophylaxis options
Subcutaneous plasma-derived C1 inhibitor: indication and dosing
Intravenous plasma-derived C1 inhibitor: indication and dosing
Subcutaneous and intravenous routes: guideline comparison
“SC administration of pdC1-INH results in more consistent plasma C1-INH concentrations than the IV route and mitigates venous access–related complications, such as thrombosis risk.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When first-line treatments are unavailable, IV pdC1-INH (approved for LTP in some countries) is a second-line option, supported by scientific evidence of its efficacy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, it has disadvantages, such as the need for venous access, high cost, and frequent administrations due to its short half-life.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote